Examining the Relationship Between FSH, Adipose Tissue Remodeling, Lean Mass Decline, and Metabolic Health

Written by: Emily Hernandez, MS, CNS

Symphony Natural Health Science and Medical Team

Reviewed by Dr. Deanna Minich, PhD, MS, CNS, FMCP, FACN

FSH receptors have been identified in human fat cells, and animal studies show blocking FSH reduces body fat and increases calorie-burning activity—but human research on FSH and body composition points in genuinely different directions depending on the population and timeframe studied [1,2].

The menopausal transition often brings frustrating changes in body composition. Despite no major changes in diet or exercise habits, fat seems to accumulate more easily around the abdomen, and muscle mass becomes harder to maintain. In addition, metabolic health may shift. This has fueled widespread interest in metabolic interventions during menopause, from GLP-1 agonists to hormone therapy, yet the endocrine drivers behind these changes remain incompletely understood.  

These changes have traditionally been attributed to declining estrogen. More recently, however, researchers have begun asking whether another hallmark of menopause—rising follicle-stimulating hormone (FSH)—may also contribute to these shifts.

Although FSH is best known for its role in reproduction, researchers have identified FSH receptors in several tissues outside the ovaries. This has prompted new questions about whether rising FSH may influence body composition and metabolism during the menopausal transition. Emerging evidence suggests that FSH may interact with adipose tissue, skeletal muscle, bone, and metabolic pathways, raising the question of whether it contributes to some of the body composition changes observed during midlife [1,2].

While much remains to be learned, FSH may represent an important—and often overlooked—piece of the metabolic puzzle during the menopausal transition.

Adipose Tissue Is More Than Fat Storage

Adipose tissue was once viewed primarily as a storage depot for excess energy. Today, it's recognized as an active endocrine organ that communicates with the rest of the body through hormones and signaling molecules, including adipokines [3]. Adipokines help regulate appetite, insulin sensitivity, inflammatory balance, energy balance, and communication with other organs throughout the body [3,4].

Different fat depots serve different functions, including energy storage, heat production, and metabolic regulation [3,5]:

• White adipose tissue primarily stores energy and produces endocrine signals.
• Brown adipose tissue specializes in thermogenesis, helping the body burn calories to generate heat.
• Beige adipose tissue can transition toward a more metabolically active, calorie-burning state under certain conditions.

Adipose tissue may directly respond to FSH signaling. Researchers have discovered functional FSH receptors (FSHR) on human and animal adipocytes [1]. This finding has expanded interest in FSH as a potential regulator of fat storage, energy expenditure, and metabolic health.

How Might FSH Influence Fat Tissue?

Experimental studies suggest that FSH signaling may affect adipocyte function through several mechanisms.

At the cellular level, FSH appears to activate pathways that promote adipocyte differentiation and lipid storage while suppressing thermogenic activity [1,6]. FSH signaling has been associated with increased expression of genes involved in fat storage, including lipoprotein lipase (LPL), fatty acid synthase (FAS), and peroxisome proliferator-activated receptor gamma (PPARγ) [6,7]. Additionally, FSH signaling may reduce the activity of uncoupling protein-1 (UCP1), which is involved in heat production and energy expenditure within brown adipose tissue [6,8].

In an animal model of menopause, blocking FSH signaling reduced body fat mass, increased thermogenic gene expression, promoted the "beiging" of white fat, and increased overall energy expenditure [6,8].

To fully understand if the same mechanisms observed in animal and cell studies translate to humans, more clinical research is required

FSH, Visceral Fat, and Metabolic Health

The relationship between FSH and adiposity in humans is more complicated than the preclinical data suggest, with findings varying by population and by how long researchers follow women over time.

Several observational studies have reported associations between higher FSH concentrations and greater waist circumference, waist-to-hip ratio, and visceral adipose tissue accumulation [2,9]. Because visceral fat is strongly associated with cardiometabolic risk, these findings have generated interest in FSH as a potential contributor to metabolic changes during menopause.

However, other studies have reported seemingly opposite findings. In the Women's Health Initiative Buffalo OsteoPerio Study, higher baseline FSH levels were associated with lower measures of adiposity, including visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), body mass index, total fat mass, and percent body fat over as many as 17 years of follow-up [10].

Further studies have shown that women with higher body mass index (BMI) have lower circulating FSH levels after menopause. One explanation is that adipose tissue can convert androgens into estrogens through aromatization, creating negative feedback on the pituitary gland and suppressing FSH production [11,12].

The relationship between FSH and adipose tissue is unlikely to be one-directional. Rising FSH may influence adipose tissue biology, but adipose tissue also feeds back into hormone regulation through estrogen production, making it difficult to separate cause and effect.

FSH, Adipokines, and Insulin Resistance

Researchers have also begun exploring how FSH may interact with adipokines—hormones released from adipose tissue that influence metabolism.

In postmenopausal women, FSH levels have been independently associated with adiponectin concentrations after adjustment for age, body mass index, and menopause duration [13]. Adiponectin plays important roles in insulin sensitivity, glucose regulation, and cardiometabolic health.

Additional studies have reported inverse associations between FSH and triglyceride concentrations during the menopausal transition [14]. Interestingly, clinical trials with FemmenessencePROTM demonstrated significant improvements in lipid biomarkers, including total cholesterol, LDL cholesterol, and HDL cholesterol [15,16]. At the time, these changes were largely attributed to the observed increases in estradiol. However, our evolving understanding of FSH biology invites a broader interpretation. Given that women taking FemmenessencePROTM also experienced significant reductions in FSH, it is worth considering whether some of the favorable cardiovascular effects may have been mediated not only by rising estradiol, but also by lowering FSH.

Relationships between FSH and fasting glucose have also been observed, although these associations often weaken after accounting for adiposity, which suggests that body fat may mediate some of the observed metabolic effects [14].

Rather than functioning solely as a reproductive hormone, FSH may participate in broader metabolic signaling networks.

Skeletal Muscle: Another Endocrine Organ

Body composition changes during menopause involve more than fat accumulation alone. Many women also experience reductions in skeletal muscle mass.

Skeletal muscle is also recognized as an endocrine organ. Muscle communicates with adipose tissue, bone, the liver, and even the brain through signaling molecules called myokines to help coordinate metabolism and energy balance [17].

Loss of lean muscle mass can contribute to changes in:

• Bone health [18]
• Immune function [19]
• Insulin sensitivity and glucose regulation [20]
• Metabolic rate [19]
• Physical function [21]

Emerging evidence suggests that rising FSH may be associated with these changes. In a cross-sectional study of peri- and postmenopausal women aged 30-70 years, appendicular lean mass index was inversely associated with FSH concentrations, whereas no significant relationship was observed with estradiol or testosterone [22]. The prevalence of sarcopenia also increased substantially during the menopause transition, affecting approximately 30% of later perimenopausal women and 27-32% of postmenopausal women compared with only 3% of women in early perimenopause [22].

While these findings do not prove causation, they suggest that FSH may serve as a marker of broader musculoskeletal changes occurring during midlife.

Does FSH Cause Menopausal Weight Gain?

At present, the evidence does not support the conclusion that FSH directly causes menopausal weight gain. Much of the strongest mechanistic evidence comes from cellular and animal studies, while most human data remain observational. Additionally, findings are not always consistent across populations.

FSH appears to be one component of a much larger endocrine network that includes adipose tissue, skeletal muscle, ovarian hormones, aging, and lifestyle factors. More research is required to fully elucidate whether FSH actively contributes to body composition changes or merely reflects hormonal shifts during menopause.

"One of the biggest shifts we need to make in midlife nutrition is moving the conversation from weight to body composition. Preserving lean muscle, supporting metabolic flexibility, and maintaining healthy adipose tissue are far more meaningful goals than chasing a number on the scale. Understanding the hormonal environment, including FSH, may help us personalize those strategies."

Supporting Healthy Body Composition During Menopause

Several evidence-based strategies remain central for supporting body composition during midlife:

Encourage Resistance Training. Resistance exercise helps preserve lean muscle mass, maintain strength and bone health, and support metabolic health [23]. 

Consider Protein Intake. Dietary protein plays a key role in muscle protein synthesis and may help support lean mass when paired with resistance training [24]. 

Discuss Factors in Metabolic Health. Balanced nutrition, regular movement, and adequate sleep remain foundational for maintaining insulin sensitivity and metabolic flexibility [25,26]. 

Directly Target Endocrine Function. FemmenessencePRO™ has been shown to promote healthy function of the hypothalamic-pituitary-thyroid-adrenal-ovarian (HPTAO) axis, with favorable effects on key endocrine biomarkers, including reductions in FSH and increases in estradiol [15,16,27]. These hormonal changes have been associated with improvements in menopausal symptoms and a healthier body weight. By influencing this interconnected endocrine network, FemmenessencePRO™ may also promote healthy body composition, metabolic resilience, and whole-body adaptation during the menopausal transition. 

Manage Chronic Stress. Supporting healthy stress resilience through adequate sleep, mindfulness practices, time outdoors, physical activity, or other stress-management techniques may help support overall metabolic and endocrine health [28,29]. 

Educate About Endocrine Disruptors. Emerging research suggests that endocrine disrupting chemicals (EDCs) may alter FSH-FSHR signaling and contribute to premature ovarian insufficiency [30,31]. Additionally, EDCs have been found to influence lipid and glucose metabolism and are associated with more adiposity [32]. 

Consider Shifting the Conversation from Weight to Body Composition. Changes in fat mass and muscle mass often occur independently of changes on the scale [33]. Waist circumference, strength, and body composition measurements may provide more meaningful insights than body weight alone. 

"Nutrition and exercise remain the foundation of healthy body composition during menopause, but they're working within a changing endocrine landscape. Emerging research on FSH reminds us that muscle, fat, and metabolism don't respond to a single hormone. They reflect the integration of nutrition, movement, recovery, and the entire endocrine system."

The Bottom Line

As our understanding of menopause continues to evolve, researchers are looking beyond estrogen alone to better understand the hormonal changes that accompany this stage of life. FSH has become part of that conversation because of its potential connections to adipose tissue, skeletal muscle, and metabolic regulation. While many questions remain unanswered, these findings highlight the complexity of body composition changes during menopause and reinforce the importance of viewing them through a broader physiological lens.

Emily Hernandez

MS, CNS · Symphony Natural Health Science and Medical Team

Board-certified nutrition specialist. MS in Nutrition Education, American University. Practice focused on functional and integrative nutrition, with clinical emphasis on hypothalamic amenorrhea, PMOS, and healthy aging for athletes. Has presented research at scientific conferences, including a poster on Symphony's circadian health study and the data on Symphony's prostate product. Background in journalism and biology before clinical nutrition.

References

1. Liu XM, Chan HC, Ding GL, et al. Aging Cell. 2015;14(3):409-420. doi:10.1111/acel.12331
2. Taneja C, Gera S, Kim SM, Iqbal J, Yuen T, Zaidi M. J Mol Endocrinol. 2019;63(3):R73-R80. doi:10.1530/JME-19-0152
3. Richard AJ, White U, Elks CM, Stephens JM. In: Feingold KR, Adler RA, Ahmed SF, et al., eds. Endotext. MDText.com, Inc.; 2020.
4. Clemente-Suárez VJ, Redondo-Flórez L, Beltrán-Velasco AI, et al. Biomedicines. 2023;11(5):1290. doi:10.3390/biomedicines11051290
5. Dowker-Key PD, Jadi PK, Alfatlawi R, Giannone RJ, Bettaieb A. Int J Mol Sci. 2026;27(4):1925. doi:10.3390/ijms27041925
6. Liu P, Ji Y, Yuen T, et al. Nature. 2017;546(7656):107-112. doi:10.1038/nature22342
7. Cui H, Zhao G, Liu R, Zheng M, Chen J, Wen J. J Lipid Res. 2012;53(5):909-917. doi:10.1194/jlr.M025403
8. Kim SM, Sultana F, Sims S, et al. J Endocrinol. 2024;262(1):e230377. doi:10.1530/JOE-23-0377
9. Gavaler JS, Rosenblum E. J Am Coll Nutr. 2003;22(4):269-276. doi:10.1080/07315724.2003.10719303
10. Yue Y, Lima SM, Hovey KM, et al. Climacteric. 2026;29(3):409-415. doi:10.1080/13697137.2025.2595986
11. Ausmanas MK, Tan DA, Jaisamrarn U, Tian XW, Holinka CF. Climacteric. 2007;10(5):427-437. doi:10.1080/13697130701610780
12. Tepper PG, Randolph JF Jr, McConnell DS, et al. J Clin Endocrinol Metab. 2012;97(8):2872-2880. doi:10.1210/jc.2012-1422
13. Huang WY, Chen DR, Kor CT, et al. Metabolites. 2020;10(10):420. doi:10.3390/metabo10100420
14. Wang X, Zhang H, Chen Y, Du Y, Jin X, Zhang Z. J Obstet Gynaecol Res. 2020;46(8):1419-1424. doi:10.1111/jog.14297
15. Meissner HO, Mscisz A, Reich-Bilinska H, et al. Int J Biomed Sci. 2006;2(4):360-374.
16. Meissner HO, Mscisz A, Reich-Bilinska H, et al. Int J Biomed Sci. 2006;2(4):375-394.
17. Horváth L, Pekař M, Švagera Z, Horká V, Mráz M, Bužga M. Physiol Res. 2025;74(suppl 1):S37-S56. doi:10.33549/physiolres.935751
18. Bettis T, Kim BJ, Hamrick MW. Osteoporos Int. 2018;29(8):1713-1720. doi:10.1007/s00198-018-4570-1
19. Argilés JM, Campos N, Lopez-Pedrosa JM, Rueda R, Rodriguez-Mañas L. J Am Med Dir Assoc. 2016;17(9):789-796. doi:10.1016/j.jamda.2016.04.019
20. Bartholomew CL, Martins C, Gower B. Obesity (Silver Spring). 2024;32(6):1156-1162. doi:10.1002/oby.24022
21. Yılmaz A, Şentürk Durmuş N, Yıldız Y, et al. Climacteric. 2026;29(1):61-66. doi:10.1080/13697137.2025.2537982
22. Park YM, Jankowski CM, Ozemek C, Hildreth KL, Kohrt WM, Moreau KL. J Appl Physiol (1985). 2020;128(5):1373-1380. doi:10.1152/japplphysiol.00315.2019
23. Erdélyi A, Pálfi E, Tűű L, et al. Nutrients. 2023;16(1):27. doi:10.3390/nu16010027
24. Kirwan RP, Mazidi M, Rodríguez García C, et al. Am J Clin Nutr. 2022;115(3):897-913. doi:10.1093/ajcn/nqab355
25. Hao S, Tan S, Li J, et al. Front Nutr. 2022;8:752500. doi:10.3389/fnut.2021.752500
26. Kravitz HM, Kazlauskaite R, Joffe H. Obstet Gynecol Clin North Am. 2018;45(4):679-694. doi:10.1016/j.ogc.2018.07.008
27. Meissner HO, Kapczynski W, Mscisz A, Lutomski J. Int J Biomed Sci. 2005;1(1):33-45.
28. Sood R, Kuhle CL, Kapoor E, et al. Climacteric. 2019;22(4):377-382. doi:10.1080/13697137.2018.1551344
29. Stute P, Lozza-Fiacco S. Maturitas. 2022;166:1-13. doi:10.1016/j.maturitas.2022.07.015
30. Roy N, Mascolo E, Lazzaretti C, et al. Front Endocrinol (Lausanne). 2021;12:791763. Published 2021 Dec 8. doi:10.3389/fendo.2021.791763
31. Tricotteaux-Zarqaoui S, Lahimer M, Abou Diwan M, et al. Front Public Health. 2024;12:1466967. Published 2024 Dec 12. doi:10.3389/fpubh.2024.1466967
32. Jaskulak M, Zimowska M, Rolbiecka M, Zorena K. Ecotoxicology and Environmental Safety. 2025;299:118401. doi:10.1016/j.ecoenv.2025.118401
33. Cruz P, Johnson BD, Karpinski SC, et al. Obesity (Silver Spring). 2011;19(11):2274-2279. doi:10.1038/oby.2011.102